| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/21/2001 | WO2001044295A2 Agonists and antagonists of the receptor gpr19 and their use in appetite control |
| 06/21/2001 | WO2001044294A2 Compositions and methods for inhibiting endothelial cell proliferation |
| 06/21/2001 | WO2001044293A2 Sodium channel proteins |
| 06/21/2001 | WO2001044291A2 Polynucleotid encoding the rg1 polypeptide |
| 06/21/2001 | WO2001044287A2 Novel polypeptides and nucleic acids encoding same |
| 06/21/2001 | WO2001044286A2 Five-helix protein |
| 06/21/2001 | WO2001044284A2 Chimeric natriuretic peptides |
| 06/21/2001 | WO2001044282A2 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 06/21/2001 | WO2001044281A2 Human secretin-like g-protein coupled receptor |
| 06/21/2001 | WO2001044278A2 Antigen preparations |
| 06/21/2001 | WO2001044274A1 Lipopeptides as antibacterial agents |
| 06/21/2001 | WO2001044272A2 Daptomycin analogs as antibacterial agents |
| 06/21/2001 | WO2001044271A2 Daptomycin analogs and their use as antibacterial agents |
| 06/21/2001 | WO2001044270A2 Methods for treating and preventing diabetic complications by use of angiotensin-related peptides |
| 06/21/2001 | WO2001044214A1 Oxadiazole derivatives and drugs containing these derivatives as the active ingredient |
| 06/21/2001 | WO2001044206A1 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 06/21/2001 | WO2001044198A1 Amphiphilic quinolylpolyamines as transfer agents for biologically active macromolecules |
| 06/21/2001 | WO2001044190A1 Anthracene derivatives as anti-cancer agents |
| 06/21/2001 | WO2001044177A2 Somatostatin analogs, radiolabelled derivatives thereof and their use |
| 06/21/2001 | WO2001043780A1 Antisense modulation of pka catalytic subunit c-alpha expression |
| 06/21/2001 | WO2001043778A1 Use of cationic lipids for intracellular protein delivery |
| 06/21/2001 | WO2001043776A1 Pharmaceutical formulation for intravenous or intramuscular octreotide administration |
| 06/21/2001 | WO2001043775A2 Hydroxide-releasing agents as skin permeation enhancers |
| 06/21/2001 | WO2001043774A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 06/21/2001 | WO2001043773A1 Tnf-alpha antagonist and lfa-1 antagonist for treating lfa-1 or tnf-alpha mediated disorder |
| 06/21/2001 | WO2001043767A1 Phosphoglycerate kinase in the treatment of disease |
| 06/21/2001 | WO2001043765A2 Method for localized administration of fibrinolytic metalloproteinases |
| 06/21/2001 | WO2001043764A2 Methods for treating pervasive development disorders |
| 06/21/2001 | WO2001043762A2 Polypeptide compositions with improved stability |
| 06/21/2001 | WO2001043761A2 Methods for treating and preventing damage to mucosal tissue |
| 06/21/2001 | WO2001043760A2 Use of ucp3 polynucleotides and polypeptides |
| 06/21/2001 | WO2001043759A2 Use of 11cby popypeptides and polynuceotides |
| 06/21/2001 | WO2001043758A1 Nutritional composition, methods of producing said composition and methods of using said composition |
| 06/21/2001 | WO2001043754A2 Pharmaceutical composition comprised of spider venoms, the production thereof, and its use for treating tumor diseases |
| 06/21/2001 | WO2001043752A1 Antisense modulation of telomeric repeat binding factor 2 expression |
| 06/21/2001 | WO2001043751A1 Novel helicobacter pylori-binding substances and use thereof |
| 06/21/2001 | WO2001043724A1 Microcapsules for sustained release of drugs |
| 06/21/2001 | WO2001043704A1 A skin care composition that mediates cell to cell communication |
| 06/21/2001 | WO2001043695A2 Peptide constructs for treating autoimmune and related diseases |
| 06/21/2001 | WO2001043694A2 Compositions and methods for caspase-induced apoptosis |
| 06/21/2001 | WO2001043691A2 Fragments and antagonists of heat shock protein 60 |
| 06/21/2001 | WO2001043527A2 Peptides and compounds that bind to the il-5 receptor |
| 06/21/2001 | WO2001019871A3 Delivery system for antidandruff agent |
| 06/21/2001 | WO2001016166A3 Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use |
| 06/21/2001 | WO2001014535A3 UDP-N-ACETYLGLUCOSAMINE: GALACTOSE-β1,3-N-ACETYLGALACTOSAMINE-α-R/(GlcNAc to GalNAc) β1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GnT3 |
| 06/21/2001 | WO2001010898A3 Compositions and methods for regulating the cell cycle and other cellular processes involving the tgf-beta family |
| 06/21/2001 | WO2001010411A3 Implantable active ingredient depot |
| 06/21/2001 | WO2001002895A8 System, apparatus, and method for correcting vision using an electro-active lens |
| 06/21/2001 | WO2001000823A8 NOVEL ISOFORMS OF THE HUMAN ESTROGEN RECEPTOR-$g(a) |
| 06/21/2001 | WO2000078972A8 Regulation with binding cassette transporter protein abc1 |
| 06/21/2001 | WO2000075281A3 Supercritical fluid-assisted nebulization and bubble drying |
| 06/21/2001 | WO2000075278B1 Gene encoding nade, p75ntr-associated cell death executor and uses thereof |
| 06/21/2001 | WO2000071719A8 Interleukin-1 hy2 materials and methods |
| 06/21/2001 | WO2000059528A8 Desleucyl glycopeptide antibiotics and methods of making same |
| 06/21/2001 | WO2000055345A9 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 06/21/2001 | WO2000052036A8 Formation and anion-exchange of crystalline echinocandin ammonium salts |
| 06/21/2001 | WO1999056697A3 Pharmaceutical composition |
| 06/21/2001 | WO1998013063A8 Cyclic peptide antitumor agent from an ascidian |
| 06/21/2001 | WO1998011243A9 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein |
| 06/21/2001 | WO1998010795A9 Tumor homing molecules, conjugates derived therefrom, and methods of using same |
| 06/21/2001 | WO1997043901A9 IceA GENE AND RELATED METHODS |
| 06/21/2001 | WO1994003601A8 Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan |
| 06/21/2001 | US20010004638 Enriched platelet wound healant |
| 06/21/2001 | US20010004456 Cytokine antagonists for the treatment of sensorineural hearing loss |
| 06/21/2001 | DE19961505A1 New antiproliferative synthetic inducible biological response amplifier protein, useful for treatment or diagnosis of hyperproliferative disease, especially tumors, atherosclerosis or psoriasis. |
| 06/21/2001 | DE19957318A1 Beeinflussung von TGF-Beta durch Proteolytische Enzyme Influence of TGF-beta by proteolytic enzymes |
| 06/21/2001 | CA2396511A1 Cytochrome p450rai-2 and related proteins |
| 06/21/2001 | CA2395585A1 Chimeric natriuretic peptides |
| 06/21/2001 | CA2395170A1 Anti-cancer agents (iii) |
| 06/21/2001 | CA2394613A1 Method for localized administration of fibrinolytic metalloproteinases |
| 06/21/2001 | CA2394574A1 Dna encoding a novel rg1 polypeptide |
| 06/21/2001 | CA2394564A1 Dna encoding snorf62 and snorf72 receptors |
| 06/21/2001 | CA2394536A1 Tnfr/opg-like molecules and uses thereof |
| 06/21/2001 | CA2394504A1 Fragments and antagonists of heat shock protein 60 |
| 06/21/2001 | CA2394466A1 Polypeptides and nucleic acids encoding same |
| 06/21/2001 | CA2394431A1 Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
| 06/21/2001 | CA2394420A1 Novel polypeptide and dna thereof |
| 06/21/2001 | CA2394350A1 Lipopeptides as antibacterial agents |
| 06/21/2001 | CA2394323A1 Peptides and compounds that bind to the il-5 receptor |
| 06/21/2001 | CA2394313A1 Novel lipopeptides as antibacterial agents |
| 06/21/2001 | CA2394269A1 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 06/21/2001 | CA2394213A1 Polypeptide compositions with improved stability |
| 06/21/2001 | CA2394167A1 Compositions and methods for inhibiting endothelial cell proliferation |
| 06/21/2001 | CA2394160A1 Human oxidoreductase proteins |
| 06/21/2001 | CA2393907A1 Novel lipopeptides as antibacterial agents |
| 06/21/2001 | CA2393808A1 Anti-cancer synthetic oligonucleotides |
| 06/21/2001 | CA2393762A1 Hydroxide-releasing agents as skin permeation enhancers |
| 06/21/2001 | CA2393333A1 Compositions and methods for caspase-induced apoptosis |
| 06/21/2001 | CA2393255A1 Nutritional composition, methods of producing said composition and methods of using said composition |
| 06/21/2001 | CA2392766A1 Novel helicobacter pylori-binding substances and use thereof |
| 06/21/2001 | CA2390689A1 Human lyases and associated proteins |
| 06/21/2001 | CA2390674A1 Antisense oligonucleotides for the inhibition of expression of type i procollagen |
| 06/21/2001 | CA2390662A1 Bcl-g polypeptides, encoding nucleic acids and methods of use |
| 06/21/2001 | CA2383936A1 Novel somatostatin analogs |
| 06/21/2001 | CA2363100A1 Genetic variants of the human fsh receptor and the influence thereof on gametogenesis |
| 06/20/2001 | EP1109021A1 Snail, new tumoral progression marker and target protein of new antitumoral compounds |
| 06/20/2001 | EP1108786A1 Novel collectin |
| 06/20/2001 | EP1108785A1 Apoptin-associating protein |
| 06/20/2001 | EP1108725A1 Novel polypeptide |
| 06/20/2001 | EP1108432A1 Method for identifying or isolating a molecule and molecules indentified thereby |